Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Lung Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Lung Cancer
    TopAbstracts in Lung Cancer 10/28/2009 - (DGNews)
    TopAbstracts in Lung Cancer 10/14/2009 - (DGNews)
    CD4 Cell Count Key to Predicting Risk of Cancers in Patients With HIV - (DGNews)
    Combination of PET/CT Scans Can Expedite Diagnosis of Lung Cancer In a Fast-Track Setting - (DGNews)
    Gefitinib Shows Significant Survival Benefits Over Carboplatin/Paclitaxel in First-Line Treatment of NSCLC: Presented at ECCO-ESMO - (DGDispatch)

    News archive

     Recent webcasts/CME - Lung Cancer

    Webcasts/CME archive

     Recent cases - Lung Cancer
      An Unusual Case of Finger Swelling: A Case Report
      Paraneoplastic Nephrotic Syndrome in Patients with Lung Cancer
      Gefitinib for Non-Small Cell Lung Cancer Patients with Liver Cirrhosis
      Occult Very Small Lung Carcinoma with a Solitary Brain Metastasis That is Clinically Diagnosed as Cavernous Hemangioma: A Case Report
      Pleuropulmonary Blastoma Type I Following Resection of Incidentally Found Congenital Lobar Emphysema

      Cases archive
        




      my personal edition > lung cancer > news
      divider

        E-Mail this DGReview to a colleague

      DGReview


      Gemcitabine/Carboplatin Combination Comparable to Standard Regimens in Treating Advanced NonSmall-Cell Lung Cancer

      A DGReview of :"Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma"
      Cancer

      08/26/2003
      By Emma Hitt, PhD


      In patients with advanced nonsmall-cell lung carcinoma (NSCLC), the combination of gemcitabine and carboplatin (GC) appears to be no more effective than mitomycin, ifosfamide, cisplatin (MIC) or mitomycin, vinblastine, cisplatin (MVP), according to the findings of a phase III trial.

      MIC and MVP are accepted treatments for patients with advanced NSCLC. Gemcitabine is a relatively new treatment with a favorable side-effect profile that acts synergistically with platinum drugs. Thus, GC is an attractive candidate for comparison with standard therapies.

      Sarah Danson, MD, Department of Medical Oncology, Christie Hospital National Health Service Trust, Manchester, United Kingdom, and colleagues studied 372 chemotherapy-naive patients with stage III/IV NSCLC who were ineligible for curative radiotherapy or surgery.

      In the study, patients were randomized to receive either 4 cycles of gemcitabine (1000 mg/m2 on days 1, 8, and 15) plus carboplatin (area under the serum concentration-time curve, 5; day 1) every 4 weeks or MIC/MVP every 3 weeks.

      Median survival was similar between the two groups (248 days in the MIC/MVP arm versus 236 days in the GC arm). Likewise, time to progression was also similar (225 days in the MIC/MVP arm versus 218 days in the GC arm).

      The 2-year survival rate was 11.8% in the MIC/MVP arm and 6.9% in the GC arm. The 1-year survival rate was 32.5% in the MIC/MVP arm and 33.2% in the GC arm.

      In the MIC/MVP arm, 33% of patients responded (4 complete responses [CRs] and 57 partial responses [PRs]), while 30% of patients in the GC arm responded (3 CRs and 54 PRs).

      Grade 3-4 symptom nonhematologic toxicity was comparable between groups, although more alopecia occurred among patients in the MIC/MVP arm. GC appeared to produce more hematologic toxicity, however, and necessitated more transfusions. No differences in performance status or disease-related symptoms were observed, although fewer inpatient stays for complications were required with GC.

      "In general, the quality-of-life data collected in the current study favored the GC combination," Dr. Danson and colleagues note. "In addition, any intervention that reduces the period of hospitalization, such as the GC regimen in the current trial, is particularly pertinent when survival tends to be short."

      The authors conclude that this study did not reveal any statistically significant differences between GC and MIC/MVP.
      Cancer 2003;98:3:542-53. "Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma"

      E-Mail this DGReview to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send